Anita Shaffer

Updates to the NCCN guidelines for patients with resectable early-stage NSCLC now include neoadjuvant and adjuvant regimens with chemotherapy, immunotherapy, and targeted therapies, which promise to change biomarker testing practice.

Six indications for immune checkpoint inhibitors granted under the FDA’s accelerated approval process that later failed confirmatory clinical trials are being reassessed as the agency continues an industry-wide evaluation of the pathway.

An update on the labeling changes from the FDA.

FDA labeling changes reflecting adverse events.

Adjuvant pertuzumab may help some early breast cancer patients.

Patients new diagnosed with cancer were able to improve quality of life and distress by through a web-based stress management program.

According to findings presented at the 2017 ASCO Annual Meeting, earlier intervention with abiraterone acetate (Zytiga) lowered the risk of death by 40% for men with high-risk advanced or metastatic prostate cancer.

According to findings presented at the 2017 ASCO Annual Meeting, patients with low-risk advanced colon cancer would benefit from a reduction in chemotherapy post-surgery, without increasing risk of recurrence, to reduce risk of neuropathy.

Recent changes to FDA labels regarding adverse events.

The adverse events report featuring FDA labeling changes for bendamustine hydrochloride, nilotinib, dinutuximab.

In a current phase II/III clinical trial for patients with advanced, recurrent, platinum-resistant ovarian cancer, the novel agent fasbretablin tromethamine is combined with bevacizumab (Avastin) and either paclitaxel or pegylated liposomal doxorubicin.

A current clinical trial for patients with non-small cell lung cancer (NSCLC) is evaluating tepotinib, a small molecule that targets an abnormality in the MET gene.